Birmingham to lead ground-breaking research into patient experience of cell therapies

Birmingham health researchers, with industry partners including health technology companies Dignio and Datatrial, have been awarded £1.1 million by UK Research & Innovation (UKRI)’s Innovate UK, to investigate patients’ experience of cell and gene therapies. The funding has been provided as part of the Industrial Strategy Challenge Fund’s Medicines Manufacturing programme. Cell and gene therapies … Continue reading “Birmingham to lead ground-breaking research into patient experience of cell therapies”

BHP founder member becomes part of the National NIHR BioResource network

The Centre for Rare Diseases at the Queen Elizabeth Hospital Birmingham, part of the BHP campus, has this week become part of the NIHR (National Institute for Health Research) BioResource network. The BioResource team at will be led by Dr Graham Lipkin while Humeira Hafsa, research nurse, will take on the role of Clinical Trials … Continue reading “BHP founder member becomes part of the National NIHR BioResource network”

Rare Disease Day celebrated at QEHB

Patients, members of the public and staff at University Hospitals Birmingham NHS Foundation Trust (UHB) braved the cold to find out more about rare diseases on 28 February. Stands representing the Centre for Rare Diseases (CfRD) and West Midlands Genomic Medicine Centre were in the Queen Elizabeth Hospital Birmingham (QEHB) Atrium to celebrate Rare Disease … Continue reading “Rare Disease Day celebrated at QEHB”

Birmingham leads UK-wide biobank in rare eye disease

A Birmingham-based Consultant Ophthalmologist and researcher, Professor Alastair Denniston, has won funding to set up a UK-wide resource to aid research into a rare disease which can lead to blindness. Two charities – Fight for Sight and the Birdshot Uveitis Society – are jointly funding the research to improve understanding of the rare, sight-threatening disease, … Continue reading “Birmingham leads UK-wide biobank in rare eye disease”

Encouraging findings presented for potential new Sjögren’s treatment

The results of a Phase IIa clinical trial have suggested a potential new antibody treatment for patients suffering from Sjögren’s syndrome. The trial was sponsored by Novartis and run in conjunction with the NIHR Translation Research Collaboration (TRC) in joint and inflammatory diseases. It is thought that up to 500,000 people in the UK, mainly … Continue reading “Encouraging findings presented for potential new Sjögren’s treatment”